

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 086 706 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
28.03.2001 Bulletin 2001/13

(51) Int. Cl.⁷: **A61K 47/12**, A61K 31/445,
A61K 45/00

(21) Application number: 99910793.1

(86) International application number:
PCT/JP99/01686

(22) Date of filing: 31.03.1999

(87) International publication number:
WO 00/59544 (12.10.2000 Gazette 2000/41)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(71) Applicant: Eisai Co., Ltd.
Tokyo 112-8088 (JP)

(72) Inventors:
• KATO, Akira
Tsukuba-shi Ibaraki 305-0035 (JP)
• HARADA, Tsutomu
Nagoya-shi Aichi 452-0803 (JP)

• MURAHASHI, Naokazu
Niwa, Ichinomiya-shi Aichi 491-0083 (JP)
• SUGAYA, Yukiko
Tsukuba-shi Ibaraki 305-0035 (JP)
• ANDO, Hidenobu
Takasaki-shi Gunma 370-0847 (JP)

(74) Representative: HOFFMANN - EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) STABILIZED COMPOSITIONS CONTAINING NOOTROPIC DRUGS

(57) The present invention provides a stable composition of an antidementia medicament. Specifically, it is a stabilized composition of an antidementia medicament comprising an antidementia medicament and an organic acid. As the organic acid, tosyllic acid, mesyllic acid, benzoic acid, salicylic acid, tartaric acid, citric acid and the like are particularly preferable.

EP 1 086 706 A1

Description

Field of Industrial Application

- 5 [0001] The present invention relates to a stabilized composition of an antimentia medicament, especially, donepezil and also to a method of stabilizing donepezil.

Prior Art

- 10 [0002] Along with the emergence of a recent social problem concerning care of senile dementia, remedies for the senile dementia have been energetically developed. Among these, donepezil has an acetylcholine esterase inhibitory effect and is highly evaluated for its usefulness as a remedy for slight to medium degree of Alzheimer's dementia. Because donepezil is a basic medicament, it is provided as a salt of hydrochloric acid.
- [0003] While, when medicaments are administered to patients, an appropriate dosage form is selected from tablets, capsule agents, powders, granules, ointments, injections, syrups and the like. In pharmaceutical preparations, various ideas are carried out corresponding to each dosage form. For example, percutaneous administration is known as one of the routes of administration to patients to whom chemicals can be orally administered with difficulty. In general, a medicament which is a salt has inferior penetrability into the skin; therefore medicaments are frequently made into a free form to formulate these drugs in percutaneous pharmaceuticals.
- 20 [0004] However, the stability of a medicament differs depending on the state of the medicament such as a salt state and a free state. The state of the medicament sometimes causes a hindrance to pharmaceutical preparations. There is the case where antimentia medicament, particularly, donepezil becomes unstable to light and/or heat when it is prepared and hence attention must be paid. In view of this situation, the inventors of the present invention have conducted intensive studies to increase the stability to light and/or heat and, as a result, found that the subject can be solved by
- 25 the following means and completed the present invention.

Disclosure of the invention


- 30 [0005] The present invention is a stabilized composition of an antimentia medicament comprising an antimentia medicament and an organic acid. The present invention is a method of stabilizing an antimentia medicament by adding an organic acid to an antimentia medicament.
- [0006] Specific examples of the antimentia medicament of the present invention include donepezil, TAK-147, CP118954 revastigmine, metrifonate, galanthamine and the like. Donepezil is generally used in the form of donepezil hydrochloride, as a therapeutic agent for Alzheimer's disease from slight to middle degrees. Chemical name thereof is 1-benzyl-4-(5,6-dimethoxyindanone-2-yl)methylpiperidine. Chemical names of TAK-147 and CP118954 are 3-[1-(phenylmethyl)piperidine-4-yl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepine-8-yl)-1-propane fumarate, and 5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazole-6-one maleate, respectively. The structural formulae of these compounds are as follows.

40


45

50


55



Donepezil



TAK-147



CP118954

[0007] No particular limitation is imposed on the organic acid used in the present invention. The examples thereof include higher fatty acid such as tosyllic acid, mesyllic acid, benzoic acid, salicylic acid, tartaric acid, citric acid, fumaric acid, maleic acid and stearic acid. Particularly, mesyllic acid, salicylic acid and citric acid are preferable. The organic acids may be used singly or by mixing two or more. Citric acid has a particularly excellent effect on the heat stability of donepezil.

[0008] The organic acid may be added in an amount of 0.1 to 10 parts by weight to 1 part by weight of the antide-mentia medicament. The amount of the organic acid is preferably 0.2 to 5 parts by weight and more preferably 0.2 to 2 parts by weight.

[0009] Although no particular limitation is imposed on the ratio of donepezil to the organic acid, the amount of the organic acid is usually 0.1 to 10 parts by weight, preferably 0.2 to 5 parts by weight and more preferably 0.2 to 2 parts by weight to 1 part by weight of donepezil.

[0010] The composition of the present invention may be used in a form such as tablets, granules, powders, oint-ments, injections or syrups. Each form is produced by a conventionally known method. For example, the granules can be produced as follows: the antide-mentia medicament is mixed with fillers such as lactose, mannitol, corn starch and crystal cellulose, a binder such as hydroxypropyl cellulose and polyvinylpyrrolidone dissolved in a solvent such as water is added thereto, mixed, kneaded and then granulated using an extrusion granulator. The ointments can be used together with the so-called ointment bases such as liquid paraffin, hydrogenated oil, vegetable oil, squalene, higher alcohols, higher fatty acid, esters of higher fatty acid, glycerol, water, antiseptics and dyes, and may be produced by a usually used method.

[0011] Syrups are prepared by dissolving the antide-mentia medicament together with sweetener such as sucrose, xylitol, mannitol and glucose in water. Further, a flavoring agent such as vanilla essence may be added if necessary.

[0012] According to the present invention, the stability of donepezil is significantly increased. The effects of the present invention will be shown by way of concrete examples.

Stabilization Test Examples

[0013] An ethanol/water (1/1) solution containing 1 mg/ml of donepezil was prepared. Tosyllic acid, mesyllic acid, benzoic acid, salicylic acid, tartaric acid and citric acid are respectively added to the solution in amount by mol equivalent to donepezil. 5 ml of each resulting solution was sealed in a transparent glass ampule. The pH of each resulting solution was 5.74, 5.84, 5.73, 5.89, 5.75 and 3.28. The pH of the solution in the case of adding no organic acid was 5.63. Each glass ampule was stored at room temperature under 1000Lux for one month to measure the content. While each same solution was separately stored at a cold place for a month and the content was measured to determine the residual ratio under illumination of light. The content was measured by using high performance liquid chromatography. The results are shown in Table 1.

Table 1

Organic acid	Storage condition	Outward appearance	Peak height	Residual ratio (%)
not added	cold place	-	41367	100.0
	121°C, 20min	-	42946	103.8
	1000Lux, 1month	++	35139	84.9
tosyllic acid	cold place	-	42967	100.0
	121°C, 20min	-	44320	103.2
	1000Lux, 1month	+	41856	97.4
mesyllic acid	cold place	-	43386	100.0
	121°C, 20min	±	44202	101.9
	1000Lux, 1month	-	43164	99.5
benzoic acid	cold place	-	42667	100.0
	121°C, 20min	-	43547	102.1
	1000Lux, 1month	++	38813	91.0
salicylic acid	cold place	-	43075	100.0
	121°C, 20min	-	43814	101.7
	1000Lux, 1month	+	43326	100.6
tartaric acid	cold place	-	44598	100.0
	121°C, 20min	-	43284	97.1
	1000Lux, 1month	-	42926	96.3
citric acid	cold place	-	42583	100.0
	121°C, 20min	-	43102	101.2
	1000Lux, 1month	-	42346	99.4

[0014] As shown in Table 1, the composition according to the present invention was improved in light stability more significantly than the samples to which nothing was added. The compositions containing each of, particularly, mesyllic acid, salicylic acid and citric acid were considered to be not almost decomposed since no peak of the decomposed materials was observed on a chromatogram.

[0015] Because percutaneous pharmaceuticals such as ointments are frequently exposed to light after they are applied to the skin, the composition according to the present invention is particularly useful.

[0016] Next, each of citric acid and maleic acid and as a control, hydrochloric acid and phosphoric acid was added to a 5 mg/5 ml donepezil solution in an amount shown in Table 2 and each resulting solution was stored at 60°C for one month to measure the content. The pH was adjusted to 3.75. The results are shown in Table 2.

Table 2

Organic acid		The ratio of the area of impurities on a chromatogram (%)
Citric acid	0.22mg	0.07
	15mg	0.09
	30mg	0.10
	45mg	0.10
malic acid	15mg	0.10
Control		
hydrochloric acid	5mg	0.42
phosphoric acid	15mg	0.43

[0017] Further, each of citric acid and as a control, hydrochloric acid was added to a 5 mg/5 ml donepezil solution containing 10% of polyvinylpyrrolidone (PVP) in an amount shown in Table 3 and each resulting solution was stored at 60°C for one month to measure the content. The results are shown in Table 3.

Table 3

Organic acid		The ratio of the area of impurities on a chromatogram (%)
Citric acid	15mg	1.34
	45mg	1.26
Control		
hydrochloric acid	5mg	2.45

[0018] It is clear from Tables 2 and 3 that the composition of the present invention is reduced in the ratio of the area of impurities on a chromatogram of high performance liquid chromatography more significantly than the control sample and is increased in stability also to heat.

Examples

[0019] The present invention will be hereinafter described in more detail by referring to Examples, however the present invention is not limited by them.

Example 1

[0020] 5 g of donepezil, 5 g of tosyllic acid, 150 g of lactose, 200 g of mannitol and 20 g of low-substituted hydroxypropyl cellulose were mixed. To the mixture was gradually added 7 g of hydroxypropyl cellulose dissolved in 50 ml of water, which was then mixed and kneaded. The kneaded mixture was charged into an extrusion granulator to produce a granule. The screen was designed to be 0.4 mm.

Example 2

[0021] 500 mg of donepezil, 200 mg of citric acid and 2000 mg of glucose were dissolved in water for injection. The pH of the solution was adjusted to 5.5 by adding 0.1N sodium hydroxide. Then, water for injection was further added to the solution such that the volume was 100 ml. Each 1 ml of the resulting solution was pipetted into an ampule. The ampule was melt-closed and then sterilized at 121°C for 15 minutes to produce an injection.

Example 3

[0022] 100 mg of donepezil, 300 mg of sodium saccharate and 50 mg of citric acid were dissolved in 50 ml purified water. The pH of the solution was adjusted to 5.5 by adding 0.1N sodium hydroxide. Then, 300 mg of methyl parabene and 20 mg of propyl parabene which were dissolved in a small amount of propylene glycol were added thereto. Purified water was further added such that the total volume of the resulting solution was 100 ml to produce a syrup.

Claims

1. A stabilized antideementia medicament composition comprising an antideementia medicament and an organic acid.
2. The composition as claimed in Claim 1, wherein the antideementia medicament is donepezil.
3. The composition as claimed in Claim 1, wherein the organic acid is at least one selected from the group consisting of tosyllic acid, mesyllic acid, benzoic acid, salicylic acid, tartaric acid and citric acid.
4. The composition as claimed in Claim 1, which is stabilized to light and/or heat.
5. A method of stabilizing an antideementia medicament, which comprises the step of adding an organic acid to an antideementia medicament.
6. The method as claimed in Claim 5, wherein the antideementia medicament is donepezil.
7. The method as claimed in Claim 5, wherein the organic acid is at least one selected from the group consisting of tosyllic acid, mesyllic acid, benzoic acid, salicylic acid, tartaric acid and citric acid.
8. The method as claimed in Claim 5, which comprises the step of stabilizing to light and/or heat.
9. The method as claimed in Claim 5, wherein the organic acid is added in an amount of 0.1 to 10 parts by weight to 1 part of the antideementia medicament.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP99/01686

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁶ A61K47/12, A61K31/445, A61K45/00 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁶ A61K47/12, A61K31/445, A61K45/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
EX	JP, 11-106353, A (Eisai Co., Ltd.), 20 April, 1999 (20. 04. 99)	1-9
A	JP, 2770571, B (Yoshitomi Pharmaceutical Industries, Ltd.), 2 July, 1998 (02. 07. 98) & WO, 9425032, A1 & CN, 1121691, A	1-9
A	JP, 7-126017, A (Maruishi Seiyaku K.K.), 16 May, 1995 (16. 05. 95)	1-9
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Δ" document member of the same patent family		
Date of the actual completion of the international search 21 June, 1999 (21. 06. 99)		Date of mailing of the international search report 6 July, 1999 (06. 07. 99)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)